295 related articles for article (PubMed ID: 30938616)
41. Canine anal sac adenocarcinomas: clinical presentation and response to therapy.
Bennett PF; DeNicola DB; Bonney P; Glickman NW; Knapp DW
J Vet Intern Med; 2002; 16(1):100-4. PubMed ID: 11822797
[TBL] [Abstract][Full Text] [Related]
42. Updated Concepts in Oncologic Surgery: Apocrine Gland Anal Sac Adenocarcinoma and Mast Cell Tumors.
Mickelson MA
Vet Clin North Am Small Anim Pract; 2022 Mar; 52(2):549-580. PubMed ID: 35082090
[TBL] [Abstract][Full Text] [Related]
43. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
Harper A; Blackwood L
J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
[TBL] [Abstract][Full Text] [Related]
44. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
Kovac RL; Ballash G; Fenger J; London C; Warry E
J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992
[TBL] [Abstract][Full Text] [Related]
45. A relatively high proportion of dogs with small apocrine gland anal sac adenocarcinoma (AGASACA) primary tumours present with locoregional lymph node metastasis.
Jones AE; Wustefeld-Janssens BG
Vet Comp Oncol; 2023 Jun; 21(2):327-331. PubMed ID: 36861227
[TBL] [Abstract][Full Text] [Related]
46. Comparison of abdominal ultrasound and magnetic resonance imaging for detection of abdominal lymphadenopathy in dogs with metastatic apocrine gland adenocarcinoma of the anal sac.
Anderson CL; MacKay CS; Roberts GD; Fidel J
Vet Comp Oncol; 2015 Jun; 13(2):98-105. PubMed ID: 23432735
[TBL] [Abstract][Full Text] [Related]
47. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
48. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
[TBL] [Abstract][Full Text] [Related]
49. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
[TBL] [Abstract][Full Text] [Related]
50. Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report.
Fuertes-Recuero M; Vázquez-Fernández E; Lizasoain-Sánz G; Arroba-Alonso A; Sánchez-López A; Martínez-de-Merlo E; Suárez-Redondo M; Ortiz-Diez G
Vet Res Commun; 2024 Jun; 48(3):1921-1927. PubMed ID: 38453822
[TBL] [Abstract][Full Text] [Related]
51. Outcome and clinical, pathological, and immunohistochemical factors associated with prognosis for dogs with early-stage anal sac adenocarcinoma treated with surgery alone: 34 cases (2002-2013).
Skorupski KA; Alarcón CN; de Lorimier LP; LaDouceur EEB; Rodriguez CO; Rebhun RB
J Am Vet Med Assoc; 2018 Jul; 253(1):84-91. PubMed ID: 29911942
[TBL] [Abstract][Full Text] [Related]
52. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
53. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
54. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
Piscoya SL; Hume KR; Balkman CE
Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
[TBL] [Abstract][Full Text] [Related]
55. Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019).
Sheppard-Olivares S; Bello NM; Johannes CM; Hocker SE; Biller B; Husbands B; Snyder E; McMillan M; McKee T; Wouda RM
Vet Rec Open; 2022 Dec; 9(1):e27. PubMed ID: 35079406
[TBL] [Abstract][Full Text] [Related]
56. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
[TBL] [Abstract][Full Text] [Related]
57. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Mitchell L; Thamm DH; Biller BJ
J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
59. Investigation of thyroid function in dogs treated with the tyrosine kinase inhibitor toceranib.
Harper A; Blackwood L; Mason S
Vet Comp Oncol; 2020 Sep; 18(3):433-437. PubMed ID: 31498949
[TBL] [Abstract][Full Text] [Related]
60. Utility of Computed Tomography versus Abdominal Ultrasound Examination to Identify Iliosacral Lymphadenomegaly in Dogs with Apocrine Gland Adenocarcinoma of the Anal Sac.
Palladino S; Keyerleber MA; King RG; Burgess KE
J Vet Intern Med; 2016 Nov; 30(6):1858-1863. PubMed ID: 27774696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
